Ocuphire Pharma Investor Presentation Deck

APX3330: Drug Development History and Patents Significant Preclinical & Clinical Data Supporting Human Safety, MOA, and PK APX3330 New Chemical Entity Ocuphire Preclinical Efficacy & Toxicology Package * Includes ZETA-1 trial 12* Phase 1 & Phase 2 Trials APX3330 IND 6 Phase 1 Trials Exposure in Humans >10,000 Subject Days at 600mg/day 5 Phase 2 Trials Studied in inflammation/hepatitis & cancer patients (Studied by Eisai & Apexian, respectively) Phase 2 Trials Patents to 2034+ Phase 3 Registration Focus on Ophthalmology NDA Filing 16

View entire presentation